2026. Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: Where the Preclinical Rationale Holds. Translational Medicine & Therapeutics Journal. 5, 2 (Apr. 2026), 28–36. DOI:https://doi.org/10.5281/zenodo.22649559.